Pancreatic cancer can be one of the hardest cancers to catch early, often giving patients few obvious warning signs until the disease has already advanced. Now, researchers have reported results from an experimental blood test that could detect early-stage pancreatic cancer with an accuracy that may open a new path toward earlier diagnosis.
The test, known as PANXEON, correctly identified early-stage pancreatic cancer in nearly 87% of cases during testing, while also detecting a precancerous condition in some patients. The findings could be especially significant because pancreatic cancer is frequently discovered after it has spread, leaving patients with fewer treatment options and a much harder road ahead.
The New Test Targets Pancreatic Cancer Earlier
PANXEON was developed to search for several biological signals associated with pancreatic cancer rather than relying on one marker alone. Researchers tested the blood-based system in nearly 1,800 people across the United States, Europe and Asia, allowing them to examine how the test performed across different groups and clinical settings. The study focused on pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer.
The results showed that PANXEON detected stage I and stage II pancreatic cancer with 86.8% sensitivity in the testing group. That means the test correctly identified most people who had early-stage disease. Researchers also found that the test could identify high-grade dysplasia, a precancerous pancreatic condition, more than 64% of the time.
That early detection potential is particularly important because pancreatic cancer frequently goes unnoticed until it has reached an advanced stage. Researchers reported that about 90% of patients have their pancreatic cancer detected after the disease has already spread to other parts of the body. By that point, treatment can become considerably more difficult.
Senior researcher Ajay Goel, chair of molecular diagnostics and experimental therapeutics at City of Hope, said the timing of diagnosis is one of the central problems surrounding the disease. “Pancreatic cancer remains so deadly largely because we find it after the window for cure has begun to close,” Goel said.
Why Pancreatic Cancer Is Called A Silent Killer
Pancreatic cancer develops in an organ located deep inside the abdomen, and early symptoms can be difficult to recognize. Some patients may not experience obvious symptoms until the cancer has progressed, making early detection a major challenge for doctors.
The disease also has one of the lowest survival rates among cancers. Researchers noted that only about 14% of patients currently live five years beyond their diagnosis. The figure reflects how strongly the timing of diagnosis can affect the treatment landscape, particularly when the disease is discovered after it has already moved beyond the pancreas.
For patients diagnosed at an earlier stage, doctors may have more opportunities to consider potentially effective treatments. Detecting the disease before symptoms appear could therefore give physicians more time to investigate what is happening and determine whether additional testing or treatment is needed.
“A stage shift is not just a statistic,” Goel said. “The earlier we find pancreatic cancer, the greater the chance that meaningful intervention is still possible.” That is the central promise behind PANXEON, although the test still needs additional research before it can become part of routine medical care.
How PANXEON Searches For Cancer
The blood test combines several different biological signals that may reveal changes associated with pancreatic cancer. Among them are genetic material shed by cancer cells and a protein known as CA19-9, which can be produced by pancreatic cancer cells.
Instead of treating each marker as a separate result, PANXEON combines the measurements into an overall score designed to estimate a person’s risk of pancreatic cancer. Researchers used artificial intelligence to help analyze the different biological signals and produce that combined assessment.
The reasoning is that cancer can leave several different traces in the body, and examining those signals together may provide more information than relying on one measurement. Goel described the approach by saying, “Most biomarkers tell you one part of the story. Combining multiple biological signals gives us a clearer picture of what may be happening in the pancreas.”
The approach could eventually be useful as an additional tool for doctors evaluating people who already have a higher risk of pancreatic cancer. However, a positive result would not automatically mean someone has cancer. Further medical evaluation would still be needed to determine what is causing the abnormal result.
The Test Also Detected A Precancerous Condition
One of the more interesting findings involved high-grade dysplasia, a condition involving abnormal cells that can precede pancreatic cancer. Researchers reported that PANXEON detected high-grade dysplasia in more than 64% of cases tested, raising the possibility that the blood test could help identify people who need closer medical monitoring.
High-grade dysplasia can be particularly important in patients with certain pancreatic cysts. Some cysts can contain cellular changes associated with a greater risk of developing invasive pancreatic cancer, which means doctors may need to determine whether a patient should undergo additional testing or surveillance.
Finding these changes before invasive cancer develops could potentially give physicians another opportunity to intervene. The idea is especially significant for people who already have known risk factors, because monitoring can sometimes be difficult when doctors do not have a simple blood-based signal to help determine who requires closer attention.
Still, the test did not identify every case of high-grade dysplasia. Its reported detection rate was 64.3%, meaning further studies will be needed to determine how reliably PANXEON can identify precancerous changes and how those results should influence patient care.
Who Could Benefit From A Test Like This?
PANXEON is not being presented as a replacement for imaging or other established medical tests. Instead, researchers see potential for it to become an additional tool for identifying people who may require further evaluation, particularly among groups already considered to have an elevated risk of pancreatic cancer.
People who could potentially benefit from closer surveillance include those with a strong family history of pancreatic cancer, certain inherited genetic risks, pancreatic cysts or chronic pancreatitis. These factors can increase concern about pancreatic cancer and may lead doctors to monitor patients more closely.
For someone in a high-risk group, a blood test could eventually provide another piece of information during that monitoring process. A concerning result could prompt additional imaging or other investigations, while a lower-risk result could potentially help doctors assess how frequently a patient needs further evaluation.
That does not mean the test is ready for widespread use. Researchers emphasized that PANXEON still needs to be validated in larger studies before it can become a routine tool. Its role would also need to be carefully defined so that doctors can balance earlier cancer detection against the possibility of unnecessary follow-up testing.
The False-Positive Problem Still Matters
The ability to detect cancer is only one part of determining whether a screening test is useful. Researchers also need to understand how often the test produces a positive result in people who do not actually have pancreatic cancer.
In the study, PANXEON’s false-positive rate was around 3% among people considered low risk. That figure increased to about 16% among people in higher-risk groups. A false positive can lead to additional scans, procedures and medical appointments, so researchers will need to determine how those results should be handled in real-world practice.
The difference between low-risk and high-risk groups also shows why the test may be more useful in carefully selected populations than as a blanket screening tool for everyone. A test designed for people with known risk factors could potentially be evaluated differently from one intended for millions of people with no known risk.
Researchers therefore have more work to do before anyone can determine how PANXEON should be used outside a research setting. The current study provides evidence that the approach can identify many early pancreatic cancers, but it does not establish that widespread use of the test would reduce pancreatic cancer deaths.
The Next Step Is Larger Clinical Testing
The findings give researchers a reason to continue studying PANXEON, but the test is still experimental. Larger prospective studies will be needed to determine whether its performance holds up when it is used across broader groups of patients and in circumstances that more closely resemble everyday medical care.
Researchers will also need to establish how the blood test should fit alongside imaging and other diagnostic tools. The goal would not necessarily be to replace existing approaches, but potentially to help doctors decide which patients need further investigation.
That distinction is important because detecting a possible cancer signal is different from diagnosing cancer. A blood test can identify a reason for concern, while doctors may still need imaging, tissue sampling or other examinations to establish exactly what is happening.
For now, PANXEON represents an experimental approach to one of pancreatic cancer’s biggest challenges: finding the disease while it is still early. If future studies confirm these results, a simple blood sample could eventually become another tool doctors use to look for a cancer that has historically been difficult to catch in time.
Earlier Detection Could Change The Conversation
The most important number from the study may not be the test’s 86.8% sensitivity on its own. It is what that performance could mean if researchers can eventually turn an experimental blood test into a reliable tool for finding pancreatic cancer before symptoms appear.
That possibility still needs to be tested. PANXEON is not yet a routine screening test, and patients should not interpret an experimental result as a replacement for medical evaluation.
But the research points toward a future in which pancreatic cancer could be detected earlier, when doctors may have more opportunities to act. For a disease where timing can make such a profound difference, finding the cancer before it has had time to spread could be the breakthrough researchers are working toward.
Sources:
- Xu, C., Mannucci, A., Han, H., Munoz, R. M., Cridebring, D., Darabi, S., Toiyama, Y., Okugawa, Y., Singh, G., Raoof, M., Park, J. O., Lin, J., Idos, G., Demeure, M. J., Borazanci, E., Evans, D. B., Tsai, S., Jun, E., Becerra, C., . . . Goel, A. (2026). Liquid biopsy for early detection of pancreatic ductal adenocarcinoma. Nature Medicine. https://doi.org/10.1038/s41591-026-04625-x
